Drug Database
EC

eculizumab (Ablyze)

✓ Approved

Cinnagen Co · C5 · 单克隆抗体

什么是 eculizumab?

eculizumab 是一种单克隆抗体,由Cinnagen Co研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Ablyze
公司Cinnagen Co
药物类别单克隆抗体, 抗体
分子靶点C5
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

eculizumab 作用于 1 个分子靶点:

C5complement C5 (C5b, C5D)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

eculizumab 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersHaemolytic uraemic syndrome✓ Approved
Nervous system disordersMyasthenia gravis✓ Approved
Renal and urinary disordersParoxysmal nocturnal haemoglobinuria✓ Approved
Nervous system disordersNeuromyelitis optica spectrum disorder✓ Approved

相关研究文献

PubMedOrphanet journal of rare diseases2026-11-17

Treatment patterns of patients with neuromyelitis optica spectrum disorder switched to inebilizumab in Japan: a claims-based retrospective study.

Sakurai Kenzo K, Gouda Maki M, Mizuno Toshimichi T, Yamamoto Kazuaki K et al.

In Japan, several biological agents with distinct mechanisms of action are available for the prevention of relapse in neuromyelitis optica spectrum disorder (NMOSD), including the B cell-depleting agent inebilizumab. Understanding the management of transitions between these agents is crucial for exploring safe switching strategies. This study examined real-world treatment patterns among patients who transitioned from non-inebilizumab biological agents to inebilizumab utilizing a claims database in Japan. Among the overall population of patients with NMOSD prescribed inebilizumab (n = 134), 19.4% (n = 26) transitioned from non-inebilizumab biological agents. Among these 26 patients, the median duration from the last prescription of the previous biological agent to the first inebilizumab prescription, designated as the index date, was 16 days for eculizumab (five patients), 48 days for satralizumab (16 patients), 56 days for ravulizumab (three patients), and 168 and 177 days for two patients treated with rituximab. Regarding oral glucocorticoid (GC) prescriptions in the switching population, the distribution of doses among patients shifted toward higher categories around the index date. The proportion of patients receiving 0 mg/day was 20%-40% during the period between month -12 and month -2, decreasing to 19.2% at month -1, and subsequently to 15.4% at the index date. Post-index date, the distribution of oral GC doses tended to revert to lower categories. During follow-up, five patients (19.2%) experienced at least one relapse. Notably, all post-switch relapses occurred exclusively in patients with a history of attacks in the year preceding the index date. This study described the treatment patterns associated with switching from non-inebilizumab biological agents to inebilizumab, indicating that such transitions are not uncommon in Japan. The switching intervals suggest that clinicians may initiate inebilizumab treatment according to the dosing interval of the previous biological agent, while also considering the mechanism and duration of action of each agent. Our observations suggest that caution should be considered at the time of switching in patients who experienced an attack in the year preceding the switch.

PMID 43040426
阅读全文 →
PubMedEuropean journal of immunology2026-11-16

Neutralising Residual Complement C5 Activity: Synergistic Potential of Orthogonal Epitope-Targeting Anti-C5 Agents.

Ghaboosh Hiba H, Kaufmann Vanessa V, Sichau Jannik J, Höchsmann Britta B et al.

Complement protein C5 activation initiates the lytic and inflammatory terminal pathway, making C5 a prime therapeutic target. Clinically approved or trial-stage C5 inhibitors (Eculizumab, Ravulizumab, Crovalimab, and OmCI) target distinct epitopes on C5. Here, we compare their binding and inhibitory potency in vitro. Individually, all agents showed substantial residual lytic C5 activity in alternative pathway (AP) haemolysis assays, though complete inhibition was achieved in classical pathway settings. Notably, Ravulizumab was slightly less effective than Eculizumab in preventing haemolysis, potentially due to its faster off-rate from C5, as observed by surface plasmon resonance. To address residual AP haemolysis, we tested all combinations of orthogonal epitope-targeting anti-C5 agents. Every combination fully inhibited lytic complement activity. Additionally, all monoclonal anti-C5 antibodies tested here bound stably to C5 activation fragments (C5b6 and sC5b-9), comparable to their interactions with C5. Residual C5 activity during strong complement activation appears to be a class effect of single-agent C5 inhibition, but it can be overcome by combining inhibitors targeting orthogonal C5 epitopes.

PMID 43036910
阅读全文 →
PubMedFrontiers in immunology2026-11-15

Tissue factor-associated neutrophil extracellular traps in dermatomyositis: procoagulant activity and endothelial activation in vitro.

Ntinopoulou Maria M, Efstathiou Lamprini L, Venetsanopoulou Aliki I AI, Simonopoulos Pavlos P et al.

Dermatomyositis (DM) is an immune-mediated myopathy characterized by inflammatory and vascular manifestations and variable systemic involvement; however, the interplay among neutrophil activation, complement, and coagulation remains unclear. We investigated whether serum from patients with DM induces tissue factor (TF)-associated neutrophil extracellular traps (NETs) and examined their functional effects in vitro. Serum from seven patients with active DM and seven matched healthy individuals was analyzed for inflammatory mediators, citrullinated histone H3 (CitH3), thrombin-antithrombin (TAT) complexes, soluble C5b-9, and DNase-I activity. Control neutrophils were exposed to DM serum and, then, NET formation, TF expression and activity, and thrombin generation were assessed. Inhibition experiments targeting complement, TF, and NETs were performed. Co-culture experiments assessed endothelial activation, while skin biopsies were examined by immunofluorescence. Patients with DM exhibited increased inflammatory mediators, CitH3, TAT complexes, and soluble C5b-9, together with reduced DNase-I activity. DM serum induced TF expression and release of TF-associated NETs by control neutrophils. DNase-I and eculizumab reduced NET formation, while eculizumab additionally decreased TF mRNA expression and NET-associated TF activity. TF-associated NETs promoted adhesion molecule expression by human aortic endothelial cells, an effect attenuated by DNase-I or TF neutralization. TF-positive NET fragments were detected in lesional DM skin but not healthy skin. These exploratory findings support a contribution of C5-dependent complement activation to TF-associated NET formation and show that these NETs can enhance thrombin generation and endothelial activation in vitro. Their relationship to clinical vasculopathy or thrombotic risk remains unknown, providing evidence for potential links between inflammation, thrombosis, and vascular injury in DM.

PMID 43031903
阅读全文 →
PubMedJournal of neuroimmunology2026-11-10

Inpatient administration of complement inhibitors as rapid-acting therapy for recurrent or refractory myasthenic exacerbation: A case series, review of the literature, and discussion of pathophysiology.

Greenberg Julia J, Seyam Muhannad M, Muppidi Srikanth S

Complement inhibitors are primarily used for symptomatic/refractory but stable myasthenic patients in the outpatient setting, however there is emerging data to suggest that complement inhibitors may be an effective rescue therapy in acute myasthenic exacerbation or crisis. We present two cases of non-ventilator-dependent patients with refractory or recurrent myasthenic exacerbation in whom eculizumab was used as a rescue therapy, review the literature to date on inpatient use of complement inhibitor therapy for myasthenic crisis/exacerbation, and discuss the pathophysiology underlying rapid clinical response. Both patients had a rapid response to eculizumab with return of ability to speak and swallow within 48 h in one patient and reduction in MG-ADL score of >6 points within 2 weeks in one patient. Both achieved minimal symptom expression (defined as MG-ADL score of 0 or 1) within weeks and had sustained response to outpatient complement inhibitor therapy. Nineteen previously published papers (58 patients) were identified. Many patients had a clinically significant reduction in MG-ADL score or other objective evidence of clinical improvement within days, and had a sustained benefit with continued outpatient therapy. Our findings add to a growing body of literature suggesting that complement inhibition may be a useful, fast-acting therapy for myasthenic exacerbation in the inpatient setting in some cases. This rapid response is likely due to functional complement blockade in patients with complement mediated neuromuscular junction damage as a primary cause of MG exacerbation/crisis.

PMID 43008373
阅读全文 →
PubMedExpert opinion on biological therapy2026-11-09

Pharmacological treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy with focus on the FDA-approved antibody narsoplimab.

Leung Garret G, Sim Joycelyn J, Kwong Yok-Lam YL

Transplantation-associated thrombotic microangiopathy (TA-TMA) is an endothelial injury syndrome after allogeneic hematopoietic stem cell transplantation (allo-HSCT), presenting as microangiopathic hemolysis, thrombocytopenia, microvascular thrombosis and multiorgan dysfunction. Dysregulated complement activation is central, rendering complement inhibition a major therapeutic target. This review summarizes the evolving concepts of the pathogenesis, diagnosis, risk stratification, and therapeutic landscape of TA-TMA, emphasizing complement-directed therapies. We discuss terminal complement inhibition with eculizumab and ravulizumab, proximal and alternative pathway inhibition with pegcetacoplan and iptacopan, and lectin pathway inhibition with narsoplimab as the only drug approved by the United States Food and Drug Administration (FDA). We critically appraise narsoplimab with respect to its pivotal trial, expanded access program, and comparative studies with other approaches. Differences in study populations, response definitions, safety ascertainment and regulatory assessments are discussed. Narsoplimab represents an important advance as the only FDA-approved treatment for TA-TMA, with consistent responses reported in different studies of high-risk patients and an acceptable safety profile. However, current evidence supporting narsoplimab is limited to single-arm studies. Future studies should employ harmonized diagnostic and response criteria, compare complement-directed strategies, and evaluate biomarker-driven early diagnosis and intervention to prevent severe organ damage that may be fatal.

PMID 43001331
阅读全文 →
PubMedCurrent medical research and opinion2026-11-09

Disease burden among patients with generalized myasthenia gravis in the United States receiving standard of care therapy: the patient perspective.

Pesa Jacqueline J, Jackson Louis L, Keenan Alexander A, Gibson Gregor G et al.

Examination of disease burden experienced by patients with gMG treated with standard of care and not with advanced biologics can inform treatment decision-making. A cross-sectional, online survey was completed by adults with generalized myasthenia gravis (gMG; patients self-reported a confirmed diagnosis) in the United States. Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab). Responses were compared between patients with mild or moderate/severe gMG (Myasthenia Gravis Activites of Daily Living [MG-ADL] score 0-4 or 5-24). Linear elastic-net regression analysis explored associations between MG-ADL score and selected variables. Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care. Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG. In a regression analysis, gMG severity was associated with severity of health-related quality of life impairment (as measured by MG-ADL score and MG-QOL-15R score; coefficient 0.103 [95% CI 0.043, 0.191]). Patients in the United States with gMG who are receiving only standard of care report a significant disease burden and impaired quality of life, with greater impairment among patients with severe gMG.

PMID 43001852
阅读全文 →

注册免费账户还可查看另外 3162 篇文献

免费注册查看全部文献 →

了解更多eculizumab